Roche expects filing for up to three new molecular entities in 2026, and accelerating its pipeline through partnerships and ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...

Please provide your email address to receive an email when new articles are posted on . There is no current treatment for children with APDS aged 4 to 11 years. Diagnostic delays have a mean of 7 ...

Source: Getty Images Breast cancer highlights from ASCO 2025 include results from DESTINY-Breast09, SERENA-6, INAVO120, VERITAC-2, and other trials. Research presented at the ASCO Annual Meeting 2025 ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, ...

The October 2024 approval of inavolisib for advanced breast cancer spotlighted a growing problem in breast oncology: Managing the hyperglycemia caused by phosphoinositide 3-kinase (PI3K)/Akt pathway ...

1 Department of Obstetrics and Gynecology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China 2 Department of Obstetrics and Gynecology, First Affiliated Hospital, Heilongjiang ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...